GlaxoSmithKline has selected a third target under its ongoing oncology discovery collaboration with Immunocore Ltd. for multiple novel targets not addressable with antibody-based technologies. Immunocore will generate a novel ImmTAC molecule against the selected target which is relevant in multiple cancers.  This is the third program to be initiated as part of the discovery collaboration from 2013. Immunocore is currently working on two other ImmTAC programmes under the agreement. The lead p...